Island Pharmaceuticals Ltd
ILPLFDrugs in Pipeline
16
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Cefoxitin
Pancreatic Cancer
Arm II Carboplatin, Paclitaxel, Cetuximab
Head and Neck Neoplasms
Escitalopram
Anxiety Disorders
B.microti diagnostic blood tests
Transfusion Transmitted Babesiosis
Tenecteplase
Ischemic Stroke
Gimatecan® (ST 1481)
Malignant Glioma
PPX (CT2103)
Glioblastoma Multiforme
PPX +TMZ+XRT
Brain Tumor
Dexamethasone oral
Breast Neoplasms
Deferoxamine Mesylate
Intracerebral Hemorrhage
Xofigo
Non Small Cell Lung Cancer With Bone Metastatses
Ixabepilone
Prostate Cancer
FOLFOXA
Locally Advanced Pancreatic Cancer
ISLA101
Dengue
Head and neck
Head and Neck Cancer
Pertuzumab
Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cefoxitin | Phase 3 | Pancreatic Cancer | - | - |
Arm II Carboplatin, Paclitaxel, Cetuximab | Phase 3 | Head and Neck Neoplasms | - | - |
Escitalopram | Phase 3 | Anxiety Disorders | - | - |
B.microti diagnostic blood tests | Phase 3 | Transfusion Transmitted Babesiosis | - | - |
Tenecteplase | Phase 2 | Ischemic Stroke | - | - |
Gimatecan® (ST 1481) | Phase 2 | Malignant Glioma | - | - |
PPX (CT2103) | Phase 2 | Glioblastoma Multiforme | - | - |
PPX +TMZ+XRT | Phase 2 | Brain Tumor | - | - |
Dexamethasone oral | Phase 2 | Breast Neoplasms | - | - |
Deferoxamine Mesylate | Phase 2 | Intracerebral Hemorrhage | - | - |
Xofigo | Phase 2 | Non Small Cell Lung Cancer With Bone Metastatses | - | - |
Ixabepilone | Phase 2 | Prostate Cancer | - | - |
FOLFOXA | Phase 2 | Locally Advanced Pancreatic Cancer | - | - |
ISLA101 | Phase 2 | Dengue | - | - |
Head and neck | Phase 2 | Head and Neck Cancer | - | - |
Pertuzumab | Phase 2 | Breast Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Island Pharmaceuticals Ltd's drug pipeline?→
CatalystAlert tracks 16 drug candidates in Island Pharmaceuticals Ltd's (ILPLF) pipeline across Phase 3, Phase 2. Its lead program is Cefoxitin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Island Pharmaceuticals Ltd's next FDA catalyst?→
Island Pharmaceuticals Ltd's (ILPLF) next tracked catalyst is a Phase 2 expected May 31, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ILPLF biotech catalysts?→
Add ILPLF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Island Pharmaceuticals Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.